Psoriatic Arthritis

Also known as: Arthritis, Psoriatic / Psoriatic arthropathy NOS / Psoriatic arthropathy / Arthropathy psoriatic / Psoriatic arthropathies / Arthropathic psoriasis

DrugDrug NameDrug Description
DB00443BetamethasoneA glucocorticoid given orally, parenterally, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. Its lack of mineralocorticoid properties makes betamethasone particularly suitable for treating cerebral edema and congenital adrenal hyperplasia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p724)
DB00297BupivacaineA widely used local anesthetic agent. [PubChem]
DB08904Certolizumab pegolCertolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha).[A176585] It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent complement fixation and antibody-mediated cytotoxicity as well as to markedly increase its half-life.[A176606] Certolizumab does not require glycosylation for active function and hence, its production is significantly more affordable when compared to other existing TNF-alpha therapies as it can be done directly in bacterial hosts such as _E. coli_.[A176606] It was developed and manufactured by UCB Pharma, first FDA approved in 2008[L4894] and updated for a new indication on March 28, 2019.[L5819]
DB01285CorticotropinCorticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis.
DB01380Cortisone acetateCortisone acetate is a steroid hormone that has both glucocoriticoid and mineral corticoid activities. Corticosteroids are used to provide relief for inflamed areas of the body. They lessen swelling, redness, itching, and allergic reactions. They are often used as part of the treatment for a number of different diseases, such as severe allergies or skin problems, asthma, or arthritis. Endogenous glucocorticoids and some synthetic corticoids have high affinity to the protein transcortin (also called CBG, corticosteroid-binding protein), whereas all of them bind albumin. Glucocorticoids also bind to the cytosolic glucocorticoid receptor.
DB00005EtanerceptDimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. Etanercept is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system. It consists of 934 amino acids.
DB00741HydrocortisoneThe main glucocorticoid secreted by the adrenal cortex. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions.
DB00065InfliximabInfliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions [A31469]. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory cytokine involved in chronic inflammatory diseases [A31469]. Its hyperactivity and enhanced signalling pathways can be observed in inflammatory diseases where it activates further pro-inflammatory cascades. By binding to both the soluble subunit and the membrane-bound precursor of TNF-α [A106], infliximab disrupts the interaction of TNF-α with its receptors and may also cause lysis of cells that produce TNF-α [A106]. Infliximab was first approved by the FDA in 1998 under the market name Remicade as an intravenous injection. It is indicated for the treatment of various inflammatory disorders such as adult or pediatric Chron's disease, adult or pediatric ulcerative colitis, rheumatoid arthritis in combination with methotrexate, ankylosing spondyliti, psoriatic arthritis, and plaque psoriasis [FDA Label]. In clinical trials, multiple infusions of infliximab displayed in a reduction of signs and symptoms of inflammatory diseases and induction of remission in patients who have had an inadequate response to alternative first-line therapies for that disorder [FDA Label]. There are currently two biosilimars of infliximab available in the US market that demonstrate a high degree of similarity to the reference product, Remicade. They are approved for all eligible indications of the reference product. Inflectra, a first biosimilar drug product, was approved in 2016. In December 2017, Ixifi, a second biosimilar that was developed by Pfizer, was granted approval by the FDA.
DB00860PrednisoloneA glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
DB00635PrednisoneA synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.
DB09029SecukinumabSecukinumab (Cosentyx) is a human monoclonal antibody designed for the treatment of uveitis, rheumatoid arthritis, ankylosing spondylitis, and psoriasis. Secukinumab is an interleukin-17A (IL-17A) inhibitor marketed by Novartis. IL-17 is a group of proinflammatory cytokines released by cells of the immune system and and exist in higher levels in many immune conditions associated with chronic inflammation. By targeting IL-17A, secukinumab has shown excellent efficacy in psoriasis by normalizing skin histology and was approved by the United States Food and Drug Administration on January 21, 2015 to treat adults with moderate-to-severe plaque psoriasis.
DB09276Sodium aurothiomalateSodium aurothiomalate is a gold compound that is used for its immunosuppressive anti-rheumatic effects. Gold Sodium Thiomalate is supplied as a solution for intramuscular injection containing 50 mg of Gold Sodium Thiomalate per mL. It is most effective in active progressive rheumatoid arthritis and of little or no value in the presence of extensive deformities or in the treatment of other forms of arthritis.
DB01284TetracosactideTetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticosteroids in the adrenal cortex. Tetracosactide exhibits the same activity as natural ACTH with regard to all its biological activities. The complex results in a product whose absorption in man is effected over a longer period of time as compared to corticotropin. Therefore, therapy may be maintained with less frequent administration.
DB00620TriamcinoloneA glucocorticoid given, as the free alcohol or in esterified form, orally, intramuscularly, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. (From Martindale, The Extra Pharmacopoeia, 30th ed, p739)
DrugDrug NameTargetType
DB00443BetamethasoneGlucocorticoid receptortarget
DB00443BetamethasoneCytochrome P450 3A4enzyme
DB00443BetamethasoneMultidrug resistance protein 1transporter
DB00443BetamethasoneCytochrome P450 19A1enzyme
DB00443BetamethasoneCytochrome P450 3A5enzyme
DB00297BupivacaineSodium channel protein type 10 subunit alphatarget
DB00297BupivacaineProstaglandin E2 receptor EP1 subtypetarget
DB00297BupivacaineCytochrome P450 3A4enzyme
DB00297BupivacaineCytochrome P450 2C19enzyme
DB00297BupivacaineCytochrome P450 2D6enzyme
DB08904Certolizumab pegolTumor necrosis factortarget
DB08904Certolizumab pegolAlcohol dehydrogenase [NADP(+)]enzyme
DB01285CorticotropinAdrenocorticotropic hormone receptortarget
DB01285Corticotropin3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2enzyme
DB01285Corticotropin25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrialenzyme
DB01285Corticotropin1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrialenzyme
DB01285CorticotropinCytochrome P450 3A4enzyme
DB01380Cortisone acetateGlucocorticoid receptortarget
DB01380Cortisone acetateCytochrome P450 3A4enzyme
DB01380Cortisone acetateCytochrome P450 3A5enzyme
DB00005EtanerceptTumor necrosis factortarget
DB00005EtanerceptLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00005EtanerceptComplement C1r subcomponenttarget
DB00005EtanerceptComplement C1q subcomponent subunit Atarget
DB00005EtanerceptComplement C1q subcomponent subunit Btarget
DB00005EtanerceptComplement C1q subcomponent subunit Ctarget
DB00005EtanerceptLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00005EtanerceptComplement C1s subcomponenttarget
DB00005EtanerceptHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00005EtanerceptLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00005EtanerceptLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00005EtanerceptLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00005EtanerceptTumor necrosis factor receptor superfamily member 1Btarget
DB00741HydrocortisoneAnnexin A1target
DB00741HydrocortisoneGlucocorticoid receptortarget
DB00741HydrocortisoneSex hormone-binding globulincarrier
DB00741HydrocortisoneCytochrome P450 3A4enzyme
DB00741HydrocortisoneCytochrome P450 3A5enzyme
DB00741HydrocortisoneCytochrome P450 3A7enzyme
DB00741HydrocortisoneMultidrug resistance protein 1transporter
DB00741HydrocortisoneSolute carrier organic anion transporter family member 1A2transporter
DB00741HydrocortisoneCytochrome P450 11B1, mitochondrialenzyme
DB00741HydrocortisoneCytochrome P450 11B2, mitochondrialenzyme
DB00741HydrocortisoneCytochrome P450 2C8enzyme
DB00741HydrocortisoneCorticosteroid-binding globulincarrier
DB00741HydrocortisoneCorticosteroid 11-beta-dehydrogenase isozyme 2target
DB00741Hydrocortisone3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1target
DB00741HydrocortisoneSolute carrier family 22 member 8transporter
DB00065InfliximabTumor necrosis factortarget
DB00860PrednisoloneCorticosteroid-binding globulincarrier
DB00860PrednisoloneCytochrome P450 3A4enzyme
DB00860PrednisoloneGlucocorticoid receptortarget
DB00860PrednisoloneSolute carrier organic anion transporter family member 1A2transporter
DB00860PrednisoloneMultidrug resistance protein 1transporter
DB00635PrednisoneGlucocorticoid receptortarget
DB00635PrednisoneCytochrome P450 3A4enzyme
DB00635PrednisoneMultidrug resistance protein 1transporter
DB00635PrednisoneSolute carrier organic anion transporter family member 1A2transporter
DB00635PrednisoneCytochrome P450 2C19enzyme
DB00635PrednisoneSerum albumincarrier
DB00635PrednisoneCorticosteroid 11-beta-dehydrogenase isozyme 1target
DB00635PrednisoneCytochrome P450 3A5enzyme
DB09276Sodium aurothiomalateUDP-glucuronosyltransferase 1-1enzyme
DB01284TetracosactideAdrenocorticotropic hormone receptortarget
DB00620TriamcinoloneCorticosteroid-binding globulincarrier
DB00620TriamcinoloneGlucocorticoid receptortarget
DB00620TriamcinoloneCytochrome P450 3A4enzyme
DB00620TriamcinoloneProstaglandin G/H synthase 2enzyme
DB00620TriamcinoloneCytochrome P450 3A5enzyme
DrugDrug NamePhaseStatusCount
DB00051Adalimumab1Not Yet Recruiting1
DB08904Certolizumab pegol1Completed2
DB12917Bimekizumab2Active Not Recruiting1
DB08908Dimethyl fumarate2Withdrawn1
DB14845Filgotinib2Active Not Recruiting1
DB11834Guselkumab2Active Not Recruiting1
DB02325Isopropyl alcohol2Completed2
DB09029Secukinumab2Active Not Recruiting1
DB05679Ustekinumab2Active Not Recruiting1
DB10318Varicella Zoster Vaccine (Live/Attenuated)2Active Not Recruiting2
DB14004Tildrakizumab2 / 3Active Not Recruiting1
DB01281Abatacept3Active Not Recruiting1
DB00051Adalimumab3Active Not Recruiting2
DB12917Bimekizumab3Active Not Recruiting2
DB12917Bimekizumab3Not Yet Recruiting1
DB08904Certolizumab pegol3Completed1
DB11834Guselkumab3Active Not Recruiting2
DB02325Isopropyl alcohol3Recruiting1
DB11569Ixekizumab3Active Not Recruiting1
DB09029Secukinumab3Active Not Recruiting2
DB09153Sodium chloride3Completed1
DB15091Upadacitinib3Active Not Recruiting2
DB05679Ustekinumab3Active Not Recruiting1
DB00051Adalimumab4Active Not Recruiting2
DB00051Adalimumab4Not Yet Recruiting1
DB00051Adalimumab4Unknown Status1
DB08904Certolizumab pegol4Unknown Status1
DB01285Corticotropin4Unknown Status1
DB00005Etanercept4Unknown Status1
DB00065Infliximab4Unknown Status1
DB11569Ixekizumab4Active Not Recruiting1
DB01097Leflunomide4Not Yet Recruiting2
DB00563Methotrexate4Active Not Recruiting1
DB00563Methotrexate4Not Yet Recruiting2
DB00959Methylprednisolone4Not Yet Recruiting1
DB09029Secukinumab4Not Yet Recruiting1
DB00795Sulfasalazine4Not Yet Recruiting2
DB00620Triamcinolone4Not Yet Recruiting1
DB01281AbataceptNot AvailableCompleted1
DB01281AbataceptNot AvailableRecruiting1
DB00051AdalimumabNot AvailableCompleted4
DB00051AdalimumabNot AvailableRecruiting2
DB00051AdalimumabNot AvailableWithdrawn1
DB00026AnakinraNot AvailableCompleted1
DB05676ApremilastNot AvailableActive Not Recruiting1
DB05676ApremilastNot AvailableRecruiting4
DB01076AtorvastatinNot AvailableWithdrawn1
DB08904Certolizumab pegolNot AvailableCompleted1
DB08904Certolizumab pegolNot AvailableRecruiting1
DB00254DoxycyclineNot AvailableCompleted1
DB00005EtanerceptNot AvailableCompleted6
DB00005EtanerceptNot AvailableRecruiting3
DB06674GolimumabNot AvailableCompleted3
DB06674GolimumabNot AvailableRecruiting2
DB06674GolimumabNot AvailableTerminated1
DB11834GuselkumabNot AvailableRecruiting1
DB00065InfliximabNot AvailableCompleted4
DB00065InfliximabNot AvailableRecruiting3
DB00331MetforminNot AvailableCompleted1
DB00563MethotrexateNot AvailableCompleted1
DB00563MethotrexateNot AvailableRecruiting2
DB00073RituximabNot AvailableCompleted1
DB00073RituximabNot AvailableRecruiting1
DB09029SecukinumabNot AvailableCompleted1
DB09029SecukinumabNot AvailableRecruiting2
DB06273TocilizumabNot AvailableCompleted1
DB06273TocilizumabNot AvailableRecruiting1
DB05679UstekinumabNot AvailableCompleted1
DB05679UstekinumabNot AvailableRecruiting3
DB00512VancomycinNot AvailableCompleted1
DB09145WaterNot AvailableCompleted2